Semaglutide Therapy for Alcohol Reduction (STAR): A Proof-of-Concept Phase II Clinical Trial.
In: Women's Health Weekly, 2023-09-12, S. 1702-1702
serialPeriodical
Zugriff:
Keywords: Addiction Research; Addiction Research - Drug Abuse; Adverse Drug Reactions; Biomarkers; Clinical Protocols; Clinical Research; Clinical Trials and Studies; Diagnostics and Screening; Drug Abuse; Drugs and Therapies; GLP-1 Receptor Agonist; Gastrointestinal Hormones; Gender Health; Gender and Health; Genetics; Glucagon; Glucagon Therapy; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose Elevating Agents; Government Agencies Offices and Entities; Health and Medicine; Hormones; Medical Records; Mental Health; Peptide Hormones; Peptide Proteins; Peptides; Pharmaceuticals; Pharmacotherapy; Placebos; Proglucagon; Proteins; Proteomics; Records as Topic; Therapeutics; Therapy; Women's Health; World Health Organization EN Addiction Research Addiction Research - Drug Abuse Adverse Drug Reactions Biomarkers Clinical Protocols Clinical Research Clinical Trials and Studies Diagnostics and Screening Drug Abuse Drugs and Therapies GLP-1 Receptor Agonist Gastrointestinal Hormones Gender Health Gender and Health Genetics Glucagon Glucagon Therapy Glucagon-Like Peptide 1 Glucagon-Like Peptides Glucose Elevating Agents Government Agencies Offices and Entities Health and Medicine Hormones Medical Records Mental Health Peptide Hormones Peptide Proteins Peptides Pharmaceuticals Pharmacotherapy Placebos Proglucagon Proteins Proteomics Records as Topic Therapeutics Therapy Women's Health World Health Organization 1702 1702 1 09/11/23 20230912 NES 230912 2023 SEP 11 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Staff editors report on the newly launched clinical trial, NCT06015893, which has the following summary description: "Background: Alcohol use disorder (AUD) is a problematic pattern of alcohol use accompanied by clinically significant medical consequences. [Extracted from the article]
Copyright of Women's Health Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Semaglutide Therapy for Alcohol Reduction (STAR): A Proof-of-Concept Phase II Clinical Trial.
|
---|---|
Zeitschrift: | Women's Health Weekly, 2023-09-12, S. 1702-1702 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1078-7240 (print) |
Sonstiges: |
|